Undisclosed EP300 degrader / Hanmi - LARVOL DELTA

[AACR] Hanmi Pharma demonstrates preclinical efficacy of TPD-based EP300 degrader, highlights synthetic lethality strategy (BioNews) - "In healthy cells, these proteins function in a complementary manner. However, in tumors with CBP gene deletions, cellular dependence on EP300 is increased, thereby enabling the use of a ‘synthetic lethality-based’ therapeutic strategy targeting EP300..Subsequent structure optimization, guided by simulation, further enhanced intracellular activity. In addition, degradation efficiency was improved through molecular designs aimed at strengthening binding affinity to EP300...The efficacy of the optimized ‘EP300 degrader’ was further validated through actual experimental studies, demonstrating both target protein degradation and inhibition of cell proliferation in relevant cancer cell lines."

Preclinical • Oncology • Solid Tumor

Hanmi Pharmaceutical unveils EP300 degrader targeting cancer cells (Chosun Biz) - "Hanmi Pharmaceutical plans to begin a GLP toxicology study, a nonclinical toxicity test, for this substance in the first quarter of next year....Hanmi Pharmaceutical also plans to conduct toxicity tests for this substance in the first quarter of next year and begin a phase 1 clinical trial in the United States in the second half of next year or early the following year."

New P1 trial • Preclinical • Small Cell Lung Cancer